Acumen Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Acumen Pharmaceuticals, Inc. (ABOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 92.96 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 6.64K shares, a 82.20% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 86.32K shares, a 4.60% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 20.91K shares, a 43.01% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 15.68K shares, a 68.35% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 156.39K shares, a 73.29% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 90.25K shares, a 1343.77% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 6.25K shares, a 49.08% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 12.28K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 6.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 92.96K shares 10-Q · filed 2026-08-12 | 113.87K shares derived: sum of 3 quarters · filed 2026-08-12 | 129.55K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 86.32K shares 10-Q · filed 2026-05-12 | 107.24K shares derived: sum of 2 quarters · filed 2026-05-12 | 122.91K shares derived: sum of 3 quarters · filed 2026-05-12 | 160.19K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 20.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 36.59K shares derived: sum of 2 quarters · filed 2026-03-26 | 73.87K shares derived: sum of 3 quarters · filed 2026-03-26 | 156.39K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 15.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 52.95K shares derived: sum of 2 quarters · filed 2025-11-12 | 135.48K shares 10-Q · filed 2025-11-12 | 172.17K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 37.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 119.80K shares 10-Q · filed 2025-08-12 | 156.50K shares derived: sum of 3 quarters · filed 2025-08-12 | 206.03K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 82.52K shares 10-Q · filed 2025-05-13 | 119.22K shares derived: sum of 2 quarters · filed 2025-05-13 | 168.75K shares derived: sum of 3 quarters · filed 2025-05-13 | |
| 2024-12-31 | 36.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 86.22K shares derived: sum of 2 quarters · filed 2025-03-27 | 90.25K shares 10-K · filed 2025-03-27 | |
| 2024-09-30 | 49.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 53.55K shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 4.03K shares 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 4.15K shares derived: sum of 2 quarters · filed 2024-03-26 | 6.25K shares 10-K · filed 2024-03-26 | |
| 2023-09-30 | 4.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 6.25K shares 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 2.10K shares 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | 12.28K shares 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |